New oral drug shows promise against deadly lassa fever
NCT ID NCT07419373
Summary
This study tests a new oral antiviral drug, ARN-75039, for treating Lassa fever in hospitalized adults in West Africa. About 135 participants will receive either a high or low dose of the new drug or the standard IV treatment, ribavirin, for 10 days. The goal is to see if the new drug is safe and reduces the virus more effectively.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LASSA FEVER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Abubakar Tafawa Balewa University Teaching Hospital
NOT_YET_RECRUITINGBauchi, Nigeria
Contact Email: •••••@•••••
-
Arisan Therapeutics
NOT_YET_RECRUITINGCarlsbad, California, 92008, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Federal Medical Centre, Owo
RECRUITINGOwo, Ondo State, Nigeria
Contact Email: •••••@•••••
-
Irrua Specialist Teaching Hospital
RECRUITINGIrrua, 310115, Nigeria
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.